BioSpace News Archive

The global Scar Treatment market size is expected to be worth around US$ 56.3 billion by 2030 from valued at US$ 20.3 billion in 2020 and is anticipated to grow at a CAGR of 15.1% during forecast period 2021 to 2030.

The global urinary tract infection testing market size is expected to hit around USD 765.9 million by 2030 from valued at USD 554.1 million in 2021, growing at a CAGR of 3.66% during the forecast period 2022 to 2030.

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has amended its credit facility with Wells Fargo Bank, N.A.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that it has commenced an underwritten public offering to sell up to $200 million of shares of its common stock.

[19-July-2022] The following statement is attributed to FDA Commissioner Robert M. Califf , M.D. SILVER SPRING, Md. , July 19, 2022 /PRNewswire/ -- In February 2022 , I rejoined the U.S. Food and Drug Administration as Commissioner of Food and Drugs, having served in the role five years earlier. Since my return, the agency has taken many significant actions that benefit the public hea

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022.

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022.

Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives to expand its reach and make it easier for healthcare providers and their patients to benefit from genetic insights.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation[1].